JP6061948B2 - κオピオイド受容体アンタゴニストとしての1−置換4−アリールピペラジン - Google Patents
κオピオイド受容体アンタゴニストとしての1−置換4−アリールピペラジン Download PDFInfo
- Publication number
- JP6061948B2 JP6061948B2 JP2014546171A JP2014546171A JP6061948B2 JP 6061948 B2 JP6061948 B2 JP 6061948B2 JP 2014546171 A JP2014546171 A JP 2014546171A JP 2014546171 A JP2014546171 A JP 2014546171A JP 6061948 B2 JP6061948 B2 JP 6061948B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently hydrogen
- nmr
- cdcl
- nhco
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明はアリールピペラジン化合物に関する。これらの化合物はオピオイド受容体アンタゴニストとして機能し、様々な疾患状態を治療するために使用することができる。
Rは、水素、OH、OC1〜6アルキル、C1〜8アルキル、C1〜8ハロアルキル、C2〜8アルケニル、C2〜8アルキニル、1つもしくは複数のY1基で置換されたアリール、アリール基が1つもしくは複数のY1基で置換されているCH2-アリール、OCOC1〜8アルキル、COC1〜8アルキル、CONH2、NHCHO、NH2、NHSO2C1〜8アルキル、またはNHCO2C1〜8アルキルであり;
Y3は、水素、Br、Cl、F、CN、CF3、NO2、SO2CH3、SO2CF3、SO2NH2、OR8、CO2R9、C1-6アルキル、NR10R11、NHCOR12、NHCO2R12、CONR13R14、またはCH2(CH2)nY2であり;
R1、R2、R3およびR4はそれぞれ独立に、以下の構造:
各Y1は独立に、水素、OH、Br、Cl、F、CN、CF3、NO2、N3、SO2CH3、SO2CF3、SO2NH2、OR8、CO2R9、Cl-6アルキル、NR10R11、NHCOR12、NHCO2Rl2、CONR13Rl4、またはCH2(CH2)nY2であるか、あるいは隣接する2つのY1基は-O-CH2-O-または-O-CH2CH2-O-基を形成し;
各Y2は独立に、水素、CF3、CO2R9、C1〜8アルキル、NR10R11、NHCOR12、NHCO2R12、CONR13R14、CH2OH、CH2OR8、COCH2R9、
各nは独立に0、1、2または3であり;
各oは独立に0、1、2または3であり;
各R8、R9、R10、R11、R12、R13、およびR14は独立に、水素、C1〜8アルキル、CH2-アリールであり、前記アリール基は1つもしくは複数の置換基OH、Br、Cl、F、CN、CF3、NO2、N3、SO2CH3、SO2CF3、SO2NH2、C1-6アルキル、またはCH2(CH2)nY2’で置換されており;
各Y2'は独立に、水素、CF3またはC1〜6アルキルであり;
R6は、水素、C1-8アルキル、1つもしくは複数のY1基で置換されたCO2C1-8アルキルアリール、アリール基が1つもしくは複数のY1基で置換されているCH2-アリール、またはCO2C1-8アルキルであり;
Gは、N、O、またはSであり、ここで、GがOまたはSである場合にはR7が存在せず;
R7は、水素、C1〜8アルキル、C2〜8アルケニル、またはC2〜8アルキニル、CH2CO2C1-8アルキル、CO2C1-8アルキル、または1つもしくは複数のY1基で置換されたCH2-アリールであり、
E1は、水素、C1〜8アルキル、C2〜8アルケニル、またはC2〜8アルキニルであり;
E2は、水素、C1〜8アルキル、C2〜8アルケニル、またはC2〜8アルキニルであり;
あるいは、E1およびE2は、一緒に=O、=S、または=NHを形成し;
AおよびBは、それぞれ独立に、CH、CW、またはNであり、但し、AおよびBのうちの1つだけがNであり得ることを条件とし;
W、X、Y、およびZは、それぞれ独立に、水素、C1〜6アルキル、C2〜6アルケニル、またはC2〜6アルキニル、OC1-6アルキル、OH、F、Cl、Br、CN、CF3、NO2、N3、SO2CH3、SO2CF3、SO2NH2、NR31R32、NHCOR33、NHCO2R34、CONR35R36、CH2(CH2)nY2、CH2O2C1-8アルキル、CO2C1-8アルキル、またはC(=NH)NR37R38であり;
R31、R32、R33、R34、R35、R36、R37およびR38は独立に、水素、C1〜6アルキル、C2〜6アルケニル、C2〜6アルキニル、1つもしくは複数の置換基OH、Br、Cl、F、CN、CF3、NO2、N3、SO2CH3、SO2CF3、SO2NH2、C1-6アルキル、またはCH2(CH2)nY2’で置換されたCH2-アリールである)。
Rは、水素、OH、OC1〜3アルキル、C1〜4アルキル、C1〜4ハロアルキル、C2〜4アルケニル、C2〜4アルキニル、1つまたは複数のY1基で置換されたアリール、アリール基が1つまたは複数のY1基で置換されているCH2-アリール、OCOC1〜4アルキル、COC1〜4アルキル、CONH2、NHCHO、NH2、NHSO2C1〜4アルキル、またはNHCO2C1〜4アルキルであり;
オピオイド受容体のアンタゴニズムおよび特異性の測定を、クローン化されたヒト受容体において、選択的アゴニスト(D-Ala2、MePhe4、Gly-ol5)エンケファリン(DAMGO、μ受容体)、シクロ[D-Pen2,D-Pen5]エンケファリン(DPDPE、δ)、および5,7,8-(-)-N-メチル-N-[7-(1-ピロリジニル)-1-オキサスピロ[4,5]デカ-8-イル]ベンゼンアセトアミド(U69,593、κ)によって生じた[35S]GTPγS結合の刺激を、選択した試験化合物が阻害する能力をモニタリングすることによって得た。データを表1に示した。
核磁気共鳴スペクトル(1H-NMRおよび13C-NMR)は、Bruker Advance DPX-300 MHzNMRスペクトロメータまたはVarian Unity Inova 500 MHz NMRスペクトロメータで測定した。化学シフトは、内部溶媒を参照して百万分の1(ppm)で記録した。マススペクトル(MS)は、APCI(大気圧化学イオン化)源もしくはESI(ターボスプレー)源を備えたPerkin-Elmer Sciex API 150 EX質量分析計で、あるいはHewlett Packard 5989 A機器で電子衝撃により、得た。元素分析は、Atlanta, GAのAtlantic Microlab社によって行われた。旋光度は、Rudolf Researchから購入したAuto Pol III旋光計で測定した。薄層クロマトグラフィー(TLC)分析は、EMDシリカゲル60 F254 TLCプレートを用いて行った。TLCの可視化は、UVランプを用いるかまたはヨウ素チャンバー内で達成した。フラッシュクロマトグラフィーは、Teledyne Iscoプレパックドシリカゲルカラムを用いるCombiFlash Companionシステムで、あるいはEM Scienceシリカゲル60Å (230-400メッシュ)で行った。溶媒系:80CMA = 80:18:2 CHCl3:MeOH:濃NH4OH。特に記載しない限り、試薬グレードの化学品を商業的な供給元から入手し、さらに精製することなく使用した。湿気および空気に感受性の全ての反応および試薬の移送は、乾燥窒素下で実施した。
[一般的手順A]
適切なフェノール(5.10 mmol)およびKOH (5.10 mmol)を、DMF (3 mL)に溶解させた後、適切な4-フルオロベンズアルデヒド(5.00 mmol)を添加した。この溶液を、密封管内で、175℃にて20分間加熱し、H2O (25 mL)に注ぎ、Et2O (75 mL)で抽出した。有機相をH2O (25 mL)、塩水(10 mL)で洗浄し、乾燥させた(Na2SO4)。濃縮によって得られた粗製残渣を、アセトン(25 mL)に溶解させ、ジョーンズ試薬(3 mL, H2SO4水溶液中の0.1 M CrO3)で処理した。TLCによって完結を確認した後、イソプロパノール(3 mL)を添加し、反応混合物を濃縮した。残渣を、5% NaOH水溶液に溶解させ、ろ過し、ろ液を50% H2SO4を用いて酸性にし、EtOAc (3 × 25 mL)で抽出した。合わせたEtOAc抽出液を、乾燥させ(Na2SO4)、濃縮して、所望の置換4-フェノキシ安息香酸を得た。
CH2Cl2 (10 mL)中の適切な酸 (0.05 mmol)およびBOP試薬(0.05 mmol) の溶液に、THF (2 mL)およびEt3N (25 μL)中のピペラジン17 (0.05 mmol)を添加した。12時間後、濃縮によって粗製残渣を得て、ヘキサン中のEtOAcグラジェントを用いるシリカゲルのフラッシュカラムクロマトグラフィーによって精製した。所望のフラクションを合わせて濃縮することによって残渣を得て、CH2Cl2に溶解させ、Et2O中の乾燥HClで処理した。溶媒を除去した後、残渣をEt2Oで粒状化させて、所望の生成物を二塩酸塩として得た。
CH2Cl2 (5 mL)中の適切な酸(0.12 mmol)およびピペラジン17 (0.12 mmol)に、HOBt (10 mol%)、EDC・HCl (0.12 mmol)、およびEt3N (40 μL)を添加した。12時間後、濃縮によって粗製残渣を得て、ヘキサン中のEtOAcグラジェントを用いるシリカゲルのフラッシュカラムクロマトグラフィーによって精製した。所望のフラクションを合わせて濃縮することによって残渣を得て、CH2Cl2に溶解させ、Et2O中の乾燥HClで処理した。溶媒を除去した後、残渣をEt2Oで粒状化させて、所望の生成物を二塩酸塩として得た。
1H NMR (CDCl3) δ 8.05 (d, 2H, J = 8.8 Hz), 7.20 (d, 2H, J = 8.4 Hz), 6.98 (d, 4H, J = 8.7 Hz), 2.37 (s, 3H).
1H NMR (CDCl3) δ 8.08 (d, 2H, J = 8.8 Hz), 7.35 (q, 1H, J = 7.7 Hz), 7.05 (d, 2H, J = 8.7 Hz), 6.96-6.76 (m, 3H).
1H NMR (CDCl3) δ 7.93 (d, 2H, J = 9.0 Hz), 7.44-6.74 (m, 6H), 2.35 (s, 3H).
1H NMR (CDCl3) δ 7.99 (d, 2H, J = 9.0 Hz), 7.00-6.80 (m, 6H).
1H NMR (CDCl3) δ 8.03 (d, 2H, J = 8.9 Hz), 7.17-7.04 (m, 2H), 7.01 (d, 2H, J = 8.9 Hz), 6.97 (d, 1H, J = 1.5 Hz), 6.94-6.86 (m, 1H).
1H NMR (CD3OD) δ 8.00 (d, 2H, J = 9.0 Hz), 7.20 (t, 1H, J = 8.1 Hz), 6.99 (d, 2H, J = 8.8 Hz), 6.67-6.60 (m, 1H), 6.55-6.47 (m, 2H).
1H NMR (CD3OD) δ 7.97 (d, 2H, J = 8.0 Hz), 6.96-6.80 (m, 5H), 2.25 (s, 3H); MS (ESI) m/z 243.3 (M - H)-.
1H NMR (CDCl3) δ 8.05 (d, 1H, J = 2.3 Hz), 7.43-7.35 (m, 2H), 7.24-7.19 (m, 1H), 7.17 (d, 1H, J = 8.2 Hz), 7.07-7.02 (m, 2H), 6.89 (dd, 1H, J = 8.7, 2.2 Hz), 2.48 (s, 3H).
1H NMR (CDCl3) δ 8.35 (d, 1H, J = 1.9 Hz), 7.41-7.30 (m, 3H), 7.24 (d, 1H, J = 8.5 Hz), 7.16 (t, 1H, J = 7.4 Hz), 7.02 (d, 2H, J = 7.7 Hz), 4.75 (s, 2H).
1H NMR (CDCl3) δ 8.38 (d, 1H, J = 2.5 Hz), 8.17 (d, 1H, J = 8.6 Hz), 7.50-7.24 (m, 4H), 7.11 (d, 2H, J = 7.6 Hz).
[α]25 D +44.4° (c 1.00, CH3OH); 1H NMR (CDCl3) δ 7.09 (t, 1H, J = 9.0 Hz), 6.52-6.45 (m, 1H), 6.40-6.30 (m, 2H), 3.92-3.84 (m, 1H), 3.22-3.10 (m, 2H), 2.78-2.70 (m, 3H), 2.56-2.45 (m, 1H), 2.38-2.27 (m, 3H), 1.68-1.58 (m, 1H), 1.08 (d, 3H, J = 6.0 Hz), 0.96 (d, 3H, J = 6.0 Hz), 0.94 (d, 3H, J = 6.0 Hz); 13C NMR (CDCl3) δ 158.2, 151.7, 129.9, 108.6, 107.2, 104.5, 62.2, 58.2, 55.0, 53.2, 51.2, 44.5, 31.9, 19.2, 18.8, 13.3; MS (ESI) m/z 278.6 (M + H)+.
1H NMR (CD3OD) δ 8.72 (d, 1H, J = 2.2 Hz), 8.34 (dd, 1H, J = 8.7, 2.4 Hz), 7.48-7.41 (m, 2H), 7.27 (t, 1H, J = 7.5 Hz), 7.15 (d, 2H, J = 8.4 Hz), 7.00 (d, 1H, J = 8.7 Hz).
1H NMR (CDCl3) δ 7.76 (d, 2H, J = 9.0 Hz), 7.36 (t, 2H, J = 9.0 Hz), 7.14 (d, 1H, J = 9.0 Hz), 7.10-6.90 (m, 5H), 6.50-6.30 (m, 4H), 4.30-4.22 (m, 1H), 3.80-3.65 (m, 1H), 3.20-2.94 (m, 2H), 2.82-2.70 (m, 2H), 2.68-2.52 (m, 1H), 2.50-2.30 (m, 3H), 2.11-1.94 (m, 1H), 0.99 (d, 3H, J = 6.0 Hz), 0.97 (d, 3H, J = 6.0 Hz), 0.88 (d, 3H, J = 6.0 Hz); 13C NMR (CDCl3) δ 167.5, 160.4, 157.5, 155.9, 151.3, 130.0, 129.8, 129.1, 128.9, 124.2, 119.8, 117.8, 108.5, 106.8, 103.9, 58.5, 57.9, 54.4, 51.4, 50.9, 43.8, 30.9, 18.9, 18.1, 12.8; MS (ESI) m/z 474.7 (M + H)+.
この遊離の塩基を二塩酸塩に変換して、灰白色の固体を得た:mp 135 °C (融解); [α]25 D +77.5° (c 0.50, CH3OH); Anal. (C29H37Cl2N3O3) C, H, N.
mp 160℃ (融解); [α]25 D +60.6° (c 0.33, CH3OH); Anal. (C30H39Cl2N3O3・1.5 H2O) C, H, N. 6b 遊離塩基: 1H NMR (CDCl3) δ 7.74 (d, 2H, J = 8.7 Hz), 6.42-6.27 (m, 3H), 7.16 (d, 2H, J = 8.3 Hz), 7.04 (t, 1H, J = 8.1 Hz), 6.94 (d, 2H, J = 8.7 Hz), 6.92 (d, 2H, J = 8.4 Hz), 4.28-4.17 (m, 1H), 3.85-3.71 (m, 1H), 3.21-2.97 (m, 2H), 2.85-2.73 (m, 2H), 2.65-2.53 (m, 1H), 2.46-2.30 (m, 3H), 2.34 (s, 3H), 2.14-2.02 (m, 1H), 0.99 (d, 3H, J = 6.7 Hz), 0.97 (d, 3H, J = 6.8 Hz), 0.89 (d, 3H, J = 6.7 Hz); 13C NMR (CDCl3) δ 167.3, 160.9, 157.1, 153.5, 151.4, 133.9, 130.4, 129.9, 129.0, 128.7, 119.8, 117.3, 108.5, 106.3, 103.4, 58.6, 57.9, 54.5, 51.3, 50.9, 43.6, 31.6, 30.8, 22.6, 20.7, 18.9, 18.0, 14.1, 12.7; MS (ESI) m/z 488.6 (M + H)+.
mp 85℃ (融解); [α]25 D +61.3° (c 0.46, CH3OH). Anal. (C29H36Cl2FN3O3・2 H2O) C, H, N. 6c 遊離塩基: 1H NMR (CDCl3) δ 7.81 (d, 2H, J = 8.8 Hz), 7.32-7.21 (m, 1H), 7.00 (t, 1H, J = 8.1 Hz), 6.93 (d, 2H, J = 8.6 Hz), 6.87-6.65 (m, 3H), 6.40 (s, 1H), 6.39 (d, 1H, J = 7.2 Hz), 6.30 (d, 1H, J = 8.0 Hz), 4.39-4.26 (m, 1H), 3.81-3.70 (m, 1H), 3.19-2.93 (m, 3H), 2.93-2.80 (m, 2H), 2.74-2.46 (m, 3H), 2.09-1.94 (m, 1H), 1.00 (d, 6H, J = 6.8 Hz), 0.90 (d, 3H, J = 6.5 Hz); 13C NMR (CDCl3) δ 167.3, 165.1, 161.9, 159.4, 157.3, 151.1, 131.6, 130.7, 130.6, 129.9, 129.7, 129.1, 118.3, 117.9, 114.8, 114.8, 111.0, 110.7, 110.4, 109.9, 107.7, 107.2, 106.9, 104.9, 58.3, 57.9, 53.8, 50.9, 50.7, 31.2, 19.0, 18.1, 13.4; MS (ESI) m/z 492.4 (M + H)+.
mp 165℃ (融解); [α]25 D +63.8° (c 0.58, CH3OH); Anal. (C30H39Cl2N3O3・1.5 H2O) C, H, N. 6d 遊離塩基: 1H NMR (CDCl3) δ 7.77 (d, 2H, J = 8.6 Hz), 7.22 (t, 1H, J = 7.8 Hz), 7.05-6.75 (m, 5H), 6.91 (d, 2H, J = 8.7 Hz), 6.41-6.35 (m, 2H), 6.32 (d, 1H, J = 8 Hz), 4.34-4.20 (m, 1H), 3.81-3.70 (m, 3H), 3.18-2.96 (m, 2H), 2.91-2.76 (m, 2H), 2.65-2.41 (m, 3H), 2.31 (s, 3H), 2.09-1.95 (m, 1H), 1.00 (d, 3H, J = 6.8 Hz), 0.99 (d, 3H, J = 6.8 Hz), 0.89 (d, 3H, J = 6.7 Hz); 13C NMR (CDCl3) δ 167.4, 160.5, 157.3, 155.9, 151.2, 140.2, 131.5, 129.9, 129.6, 129.5, 128.9, 128.8, 125.0, 124.7, 120.4, 120.4, 117.7, 117.2, 116.7, 116.7, 109.4, 107.2, 104.5, 58.4, 57.9, 54.0, 50.9, 31.5, 31.1, 29.0, 25.3, 22.6, 21.3, 19.0, 18.1, 14.1, 13.2; MS (ESI) m/z 488.6 (M + H)+.
mp 145℃ (融解); [α]25 D +57.8° (c 0.86, CH3OH). Anal. (C30H39Cl2N3O4・2.5 H2O) C, H, N. 6e 遊離塩基: 1H NMR (CDCl3) δ 7.76 (d, 2H, J = 8.8 Hz), 7.21-7.12 (m, 1H), 7.06-6.88 (m, 4H), 6.84 (d, 2H, J = 8.8 Hz), 6.39 (s, 1H), 6.38 (d, 1H, J = 7.5 Hz), 6.30 (d, 1H, J = 7.8 Hz), 4.37-4.23 (m, 1H), 3.82-3.69 (m, 1H), 3.74 (s, 3H), 3.20-2.82 (m, 5H), 2.74-2.47 (m, 3H), 2.07-1.93 (m, 1H), 0.99 (d, 6H, J = 6.9 Hz), 0.88 (d, 3H, J = 6.4 Hz); 13C NMR (CDCl3) δ 167.6, 161.0, 157.4, 151.7, 151.1, 143.7, 131.5, 129.9, 128.8, 128.1, 125.8, 125.6, 122.1, 1212., 121.3, 121.2, 116.1, 115.8, 113.0, 109.7, 107.6, 104.8, 64.4, 58.4, 57.9, 55.9, 55.9, 53.9, 50.9, 50.7, 44.3, 31.6, 31.2, 30.6, 22.6, 19.1, 19.0, 18.1, 13.7, 13.2; MS (ESI) m/z 504.6 (M + H)+.
mp 145℃ (融解); [α]25 D +57.6° (c 0.59, CH3OH); Anal. (C30H39Cl2N3O4・2 H2O) C, H, N. (6f). 遊離塩基: 1H NMR (CDCl3) δ 7.77 (d, 2H, J = 8.7 Hz), 7.25 (t, 1H, J = 7.9 Hz), 7.05 (t, 1H, J = 8.0 Hz), 7.01 (d, 2H, J = 8.8 Hz), 6.74-6.56 (m, 3H), 6.43-6.28 (m, 3H), 4.27-4.15 (m, 1H), 3.85-3.74 (m, 1H), 3.77 (s, 3H), 3.23-3.11 (m, 1H), 3.11-2.98 (m, 1H), 2.84-2.71 (m, 2H), 2.66-2.54 (m, 1H), 2.51-2.30 (m, 3H), 2.11-1.94 (m, 1H), 0.99 (d, 2H, J = 6.7 Hz), 0.98 (d, 2H, J = 6.7 Hz), 0.89 (d, 2H, J = 6.5 Hz); 13C NMR (CDCl3) δ 167.3, 161.1, 160.1, 157.3, 157.0, 151.4, 130.4, 129.9, 129.5, 128.8, 128.7, 118.1, 118.0, 111.7, 109.9, 108.6, 106.2, 106.2, 105.7, 103.3, 58.6, 57.8, 55.4, 54.5, 51.3, 50.9, 43.5, 30.8, 18.9, 18.0, 12.8; MS (ESI) m/z 504.5 (M + H)+.
mp 185℃ (融解); [α]25 D +62.4° (c 1.60, CH3OH). Anal. (C29H37Cl2N3O4・1.5 H2O) C, H, N. 6g 遊離塩基: 1H NMR (CD3OD) δ 7.81 (d, 2H, J = 8.8 Hz), 7.03 (t, 1H, J = 8.1 Hz), 6.95-6.87 (m, 4H), 6.85-6.79 (m, 2H), 6.46-6.26 (m, 3H), 4.26-4.16 (m, 1H), 3.85-3.72 (m, 1H), 3.18-2.93 (m, 3H), 2.90-2.78 (m, 3H), 2.76-2.62 (m, 1H), 2.58-2.40 (m, 3H), 1.98-1.93 (m, 1H), 3.54 (d, 3H, J = 7.1 Hz), 1.00 (d, 3H, J = 7.0 Hz), 0.92 (d, 3H, J = 6.6 Hz); 13C NMR (CD3OD) δ 170.0, 163.3, 159.3, 155.7, 152.9, 149.3, 130.8, 130.3, 122.7, 117.4, 117.3, 110.3, 108.3, 105.7, 60.8, 59.2, 55.3, 53.0, 52.8, 46.1, 46.1, 33.0, 32.8, 23.7, 20.1, 18.8, 14.5, 13.5; MS (ESI) m/z 490.7 (M + H)+.
mp 173℃ (融解); [α]25 D +60.0° (c 1.50, CH3OH). Anal. (C29H37Cl2N3O4・CH3OH) C, H, N. 6h 遊離塩基: 1H NMR (CD3OD) δ 7.8 (d, 2H, J = 8.8 Hz), 7.13-6.81 (m, 7H), 6.45-6.26 (m, 3H), 4.26-4.15 (m, 1H), 3.85-3.71 (m, 1H), 3.18-2.94 (m, 3H), 2.91-2.79 (m, 3H), 2.77-2.63 (m, 1H), 2.58-2.39 (m, 3H), 1.96-1.82 (m, 1H), 1.02 (d, 3H, J = 7.0 Hz), 0.99 (d, 3H, J = 6.9 Hz), 0.92 (d, 3H, J = 6.4 Hz); 13C NMR (CD3OD) δ 170.0, 162.5, 159.3, 152.9, 150.7, 143.8, 140.0, 130.8, 130.2, 129.8, 127.1, 123.2, 121.3, 118.5, 117.0, 110.3, 108.3, 105.7, 101.4, 60.8, 59.2, 55.3, 53.0, 52.8, 46.0, 32.8, 20.1, 18.8, 13.5; MS (ESI) m/z 490.7 (M + H)+.
mp 132℃ (融解); [α]25 D +59.6° (c 1.51, CH3OH); Anal. (C29H37Cl2N3O4・2 H2O) C, H, N. 6i 遊離塩基: 1H NMR (CD3OD) δ 7.85 (d, 2H, J = 8.7 Hz), 7.18 (t, 1H, J = 8.0 Hz), 7.07-6.97 (m, 3H), 6.65-6.59 (m, 1H), 6.53-6.37 (m, 4H), 6.34-6.29 (m, 1H),4.28-4.17 (m, 1H), 3.85-3.74 (m, 1H), 3.19-2.94 (m, 3H), 2.93-2.66 (m 4H), 2.63-2.42 (m, 3H), 1.98-1.84 (m, 1H), 1.02 (d, 3H, J = 6.8 Hz), 1.00 (d, 3H, J = 6.9 Hz), 0.93 (d, 3H, J = 6.4 Hz); 13C NMR (CD3OD) δ 169.9, 161.9, 160.3, 159.3, 158.5, 152.8,131.6, 130.9, 130.5, 130.4, 118.7, 112.5, 111.7, 110.4, 108.4, 108.0, 105.8, 104.6, 98.2, 60.8, 59.2, 55.3, 53.0, 52.7, 32.8, 20.1, 18.8, 13.6; MS (ESI) m/z 490.7 (M + H)+.
mp 125℃ (融解); [α]25 D +64.5° (c 1.01, CH3OH). Anal. (C30H39Cl2N3O4・H2O) C, H, N. 6j 遊離塩基: 1H NMR (CDCl3) δ 7.74 (d, 2H, J = 8.8 Hz), 7.08-6.84 (m, 7H), 6.48 (br s, 1H), 6.41-6.24 (m, 3H), 4.30-4.17 (m, 1H), 3.81-3.70 (m, 1H), 3.80 (s, 3H), 3.19-2.93 (m, 2H), 2.86-2.56 (m, 4H), 2.54-2.30 (m, 3H), 2.10-1.94 (m, 1H), 1.01-0.93 (m, 6H), 0.87 (d, 3H, J = 6.4 Hz); 13C NMR (CDCl3) δ 167.4, 161.4, 157.2, 156.5, 151.3, 149.0, 129.9, 128.8, 121.4, 116.7, 115.0, 108.9, 106.7, 103.8, 58.44, 57.9, 57.8, 55.7, 54.3, 51.1, 50.9, 43.8, 43.8, 30.9, 18.9, 18.0, 12.9; MS (ESI) m/z 504.7 (M + H)+.
mp 88℃ (融解); [α]25 D +62.1° (c 1.51, CH3OH). Anal. (C30H39Cl2N3O3・H2O) C, H, N. 6k 遊離塩基: 1H NMR (CDCl3) δ 7.70 (s, 1H), 7.56 (d, 1H, J = 8.5 Hz), 7.32 (t, 2H, J = 8.3 Hz), 7.09 (t, 1H, J = 7.5 Hz), 7.03 (t, 1H, J = 7.9 Hz), 6.92 (d, 2H, J = 8.1 Hz), 6.81 (d, 1H, J = 8.4 Hz), 6.46 (br s, 1H), 6.41-6.28 (m, 3H), 4.32-4.17 (m, 1H), 3.83-3.69 (m, 1H), 3.18-2.95 (m, 2H), 2.86-2.58 (m, 3H), 2.52-2.32 (m, 3H), 2.27 (s, 3H), 2.10-1.96 (m, 1H), 1.02-0.93 (m, 6H), 0.89 (d, 3H, J = 6.4 Hz); 13C NMR (CDCl3) δ 167.6, 157.9, 157.3, 151.3, 130.3, 129.9, 129.7, 129.7, 129.5, 126.0, 123.4, 118.4, 118.1, 108.7, 106.8, 103.9, 103.2, 96.8, 58.5, 57.9, 54.3, 51.2, 50.9, 30.9, 18.9, 18.0, 16.2, 12.9; MS (ESI) m/z 488.6 (M + H)+.
mp 154-158℃ (融解), [α]25 D +63.2° (c 0.95, CH3OH). Anal. (C30H38Cl3N3O3・H2O) C, H, N. 6l 遊離塩基: 1H NMR (CDCl3) δ 7.87 (s, 1H), 7.60 (d, 1H, J = 8.5 Hz), 7.23 (t, 1H, J = 7.7 Hz), 7.04 (t, 1H, J = 8.0 Hz), 6.97 (d, 1H, J = 7.4 Hz), 6.88 (d, 1H, J = 8.5 Hz), 6.84-6.76 (m, 2H), 6.40 (d, 1H, J = 8.2 Hz), 6.35-6.25 (m, 3H), 4.26-4.12 (m, 1H), 3.85-3.74 (m, 1H), 3.17 (d, 1H, J = 11.7 Hz), 3.04 (t, 1H, J = 10.0 Hz), 2.77 (t, 2H, J = 8.8 Hz), 2.64-2.52 (m, 1H), 2.48-2.29 (m, 3H), 2.33 (s, 3H), 2.11-1.97 (m, 1H), 1.05-0.93 (m, 6H), 0.89 (d, 3H, J = 6.4 Hz); 13C NMR (CDCl3) δ 166.2, 157.0, 155.7, 151.4, 140.3, 130.7, 129.9, 129.7, 129.5, 126.7, 125.2, 125.1, 119.7, 119.0, 116.0, 108.6, 106.3, 103.4, 58.5, 57.9, 54.5, 51.5, 50.9, 43.6, 30.8, 21.4, 18.9, 18.1, 12.8; MS (ESI) m/z 522.4 (M + H)+.
mp 179-183℃ (融解), [α]25 D +56.5° (c 1.35, CH3OH). Anal. (C30H39Cl2N3O4・H2O) C, H, N. 6m 遊離塩基: 1H NMR (CDCl3) δ 7.70 (d, 2H, J = 8.8 Hz), 7.01 (t, 1H, J = 8.1 Hz), 6.96-6.82 (m, 4H), 6.72 (s, 1H), 6.41-6.26 (m, 4H), 4.27-4.14 (m, 1H), 3.70-3.58 (m, 1H), 3.06 (d, 1H, J = 11.7 Hz), 2.95 (t, 1H, J = 10.5 Hz), 2.71 (d, 2H, J = 10.6 Hz), 2.56 (t, 1H, J = 11.3 Hz), 2.45-2.18 (m, 3H), 2.21 (s, 3H), 2.07-1.93 (m, 1H), 1.00-0.91 (m, 6H), 0.81 (d, 3H, J = 6.4 Hz); 13C NMR (CDCl3) δ 167.5, 160.2, 157.2, 151.4, 145.7, 142.1, 130.5, 129.9, 129.2, 128.8, 128.8, 126.2, 120.9, 116.9, 116.7, 108.8, 106.7, 103.8, 58.6, 57.9, 54.4, 51.4, 51.0, 43.9, 30.9, 20.6, 18.9, 18.0, 12.9; MS (ESI) m/z 504.6 (M + H)+.
1H NMR (CDCl3) δ 8.29 (d, 1H, J = 2.6 Hz), 8.13 (d, 1H, J = 8.7 Hz), 7.94 (d, 1H, J = 9.0 Hz), 7.45-7.36 (m, 2H), 7.32 (dd, 1H, J = 8.6, 2.9 Hz), 7.21 (t, 1H, J = 7.3 Hz), 7.11-7.03 (m, 3H), 6.43 (dd, 1H, J = 8.2, 1.6 Hz), 6.32 (s, 1H), 6.25 (d, 1H, J = 7.2 Hz), 4.67 (br s, 1H), 4.26-4.12 (m, 1H), 3.92-3.78 (m, 1H), 3.27-3.14 (m, 1H), 3.06 (td, 1H, J = 11.4, 3.3 Hz), 2.89 (d, 1H, J = 11.4 Hz), 2.78 (d, 1H, J = 11.0 Hz), 2.62-2.52 (m, 1H), 2.48-2.28 (m, 3H), 2.15-1.95 (m, 1H), 1.01 (d, 3H, J = 4.7 Hz), 0.98 (d, 3H, J = 4.7 Hz), 0.93 (d, 3H, J = 6.3 Hz); 13C NMR (CDCl3) δ 164.1, 157.7, 156.5, 155.2, 151.4, 144.3, 138.8, 130.2, 129.7, 124.9, 124.9, 123.5, 119.7, 108.0, 106.3, 103.5, 59.3, 58.2, 54.3, 51.4, 50.9, 43.5, 30.7, 19.3, 17.7, 12.6. MS (ESI) m/z 476.0 (M + H)+。
この遊離塩基を酸塩酸塩に変換して、黄褐色固体を得た(121 mg, 31%)。
mp 95℃ (融解); [α]25 D +73.1° (c 0.67, CH3OH). Anal. (C28H37Cl3N4O3・0.5 EtOAc) C, H, N.
mp 168-170℃ (融解), [α]25 D +59.7° (c 1.55, CH3OH). Anal. (C29H39Cl3N4O3・2.5H2O) C, H, N. 7b 遊離塩基: 1H NMR (CDCl3) δ 8.57 (d, 1H, J = 2.3 Hz), 8.12 (dd, 1H, J = 8.6, 2.5 Hz), 7.41 (t, 2H, J = 7.9 Hz), 7.23 (t, 1H, J = 7.4 Hz), 7.16-7.10 (m, 2H), 7.04 (t, 1H, J = 8.0 Hz), 6.91 (d, 1H, J = 8.6 Hz), 6.38 (d, 1H, J = 8.0 Hz), 6.33-6.23 (m, 3H), 4.27-4.12 (m, 1H), 3.83-3.71 (m, 1H), 3.19-3.09 (m, 1H), 3.06-2.95 (m, 1H), 2.75 (d, 2H, J = 10.8 Hz), 2.62-2.49 (m, 1H), 2.46-2.25 (m, 3H), 2.11-1.96 (m, 1H), 1.01-0.93 (m, 6H), 0.86 (d, 3H, J = 6.4 Hz); 13C NMR (CDCl3) δ 165.7, 165.6, 157.1, 153.5, 151.4, 146.4, 139.0, 129.9, 129.8, 125.8, 125.3, 121.4, 111.1, 108.6, 106.4, 103.5, 58.5, 57.8, 54.5, 51.4, 50.9, 43.6, 30.7, 18.8, 18.0, 12.8; MS (ESI) m/z 475.7 (M + H)+.
適切なフェノール(1.4 mmol)およびKOH (1.1 mmol)を、DMF (1.5 mL)に溶解させた後、適切な4-フルオロベンズアルデヒド(1 mmol)を添加した。この溶液を密封管内で175℃にて20分間加熱し、H2O (25 mL)に注ぎ、Et2O (75 mL)で抽出した。有機相をH2O (25 mL)、塩水(10 mL)で洗浄し、無水にした(Na2SO4)。この粗製残渣を5:1アセトニトリル:水(6 mL)に、NaH2PO4 (36 mg)およびH2O2 (150 μL, 30%)と共に溶解させた。氷浴中、水(1.5 mL)中のNaClO2 (158 mg)の溶液をゆっくりと添加した。室温で12時間経過させた後、反応をNa2S2O3で停止させ、塩水で希釈し、EtOAcで抽出した。水性塩基への抽出、酸性化、およびEtOAcへの抽出によって単離した。
1H NMR (CDCl3) δ 8.07 (d, 2H, J = 8.9 Hz), 7.29-7.13 (m, 4H), 6.99 (d, 2H, J = 8.8 Hz); MS (ESI) m/z 231.6 (M - H)-.
1H NMR (CDCl3) δ 8.11 (d, 2H, J = 8.9 Hz), 7.56-7.43 (m, 2H), 7.34 (s, 1H), 7.15 (t, 1H, J = 8.6 Hz), 7.05 (d, 2H, J = 8.8 Hz); MS (ESI) m/z 281.4 (M - H)-.
1H NMR (CDCl3) δ 8.10 (d, 2H, J = 8.7 Hz), 7.32 (t, 1H, J = 8.1 Hz), 7.21-7.16 (m, 1H), 7.08 (t, 1H, J = 2.0 Hz), 7.04 (d, 2H, J = 8.8 Hz), 7.00-6.95 (m, 1H); MS (ESI) m/z 247.3 (M - H)-.
1H NMR (CDCl3) δ 8.10 (d, 2H, J = 8.7 Hz), 7.37-7.21 (m 3H), 7.07-6.99 (m, 3H); MS (ESI) m/z 291.1 (M - H)-.
1H NMR (CDCl3) δ 7.98 d, 2H, J = 8.8 Hz), 7.10-6.95 (m, 2H), 6.89 (d, 2H, J = 8.8 Hz), 6.82-6.75 (m, 1H), 2.08 (s, 3H); MS (ESI) m/z 243.3 (M - H)-.
1H NMR (CDCl3) δ 8.06 (d, 2H, J = 9.0 Hz), 6.99 (d, 2H, J = 9.0 Hz), 6.84 (s, 1H), 6.70 (s, 2H), 2.32 (s, 3H).
1H NMR (CDCl3) δ 8.01 (s, 1H), 7.88 (d, 1H, J = 8.4 Hz), 7.24 (t, 1H, J = 8.1 Hz), 6.97 (d, 1H, J = 7.4 Hz), 6.86-6.77 (m, 3H), 2.35 (s, 3H), 2.34 (s, 3H).
1H NMR (CDCl3) δ , 3.96 (s, 3H).
1H NMR (CDCl3) δ 7.77 (d, 1H, J = 2.0 Hz), 7.59 (dd 1H, J = 8.5, 2.1 Hz), 7.26 (t, 1H, J = 7.9 Hz), 6.99 (d, 1H, J = 7.3 Hz), 6.88 (s, 1H), 6.87-6.84 (m, 1H), 6.82 (d, 1H, J = 8.5 Hz), 2.35 (s, 3H).
1H NMR (CD3OD) δ 7.93 (d, 1H, J = 8.6 Hz), 7.27 (t, 1H, J = 7.8 Hz), 7.02 (d, 1H, J = 7.7 Hz), 6.89-6.73 (m, 4H), 2.54 (s, 3H), 2.34 (s, 3H).
1H NMR (CDCl3) δ 8.10 (d, 1H, J = 8.8 Hz), 7.30 (t, 1H, J = 8.2 Hz), 7.05 (d, 1H, J = 7.7 Hz), 6.93-6.84 (m, 2H), 6.66 (d, 1H, J = 2.1 Hz), 6.60 (dd, 1H, J =8.7, 2.2 Hz), 4.00 (s, 3H), 2.37 (s, 3H).
1H NMR (CDCl3) δ 10.51 (bs, 1H), 7.86 (d, 1H, J = 8.9 Hz), 7.28 (t, 1H, J = 7.7 Hz), 7.04 (d, 1H, J = 7.5 Hz), 6.93-6.86 (m, 2H), 6.55 (dd, 1H, J = 8.9, 2.2 Hz), 6.44 (d, 1H, J = 2.3 Hz), 2.37 (s, 3H).
1H NMR (CDCl3) δ 7.69 (s, 1H), 7.62 (d, 1H, J = 8.4 Hz), 7.12-6.70 (m, 6H), 3.97 (s, 3H).
1H NMR (CDCl3) δ 8.22 (d, 1H, J = 2.1 Hz), 7.92 (dd, 1H, J = 8.5, 2.0 Hz), 7.21-7.05 (m, 2H), 6.98-6.77 (m, 4H).
1H NMR (CDCl3) δ 7.73-7.66 (m, 2H), 6.99-6.85 (m, 3H), 6.76 (s, 1H), 3.97 (s, 3H), 2.24 (s, 3H).
1H NMR (CDCl3) δ 8.21 (s, 1H), 7.92 (d, 1H, J = 8.0 Hz), 7.01-6.89 (m, 3H), 6.76 (s, 1H), 2.26 (s, 3H).
mp 156-159℃ (融解), [α]25 D +64.6° (c 0.395, CH3OH). Anal. (C29H36Cl2FN3O3・H2O) C, H, N. 19a 遊離塩基: 1H NMR (CDCl3) δ 7.75 (d, 2H, J = 8.7 Hz), 7.24-7.07 (m, 3H), 7.03 (t, 1H, J = 8.0 Hz), 6.94 (d, 2H, J = 8.7 Hz), 6.43-6.22 (m, 4H), 4.27-4.15 (m, 1H), 3.83-3.72 (m, 1H), 3.20-3.09 (m, 1H), 3.08-2.96 (m, 1H), 2.95-2.71 9(m, 2H), 2.63-2.51 (m, 1H), 2.45-2.26 (m, 3H), 2.11-1.98 (m, 1H), 1.02-0.94 (m, 6H), 0.88 (d, 3H, J = 6.4 Hz); 13C NMR (CDCl3) δ 167.2, 160.2, 157.1, 151.4, 129.9, 129.5, 128.8, 12.58, 125.0, 122.8, 117.4, 117.2, 116.4, 108.5, 106.3, 103.4, 58.5, 57.8, 54.5, 51.3, 50.9, 43.6, 30.8, 18.9, 18.0, 12.8; MS (ESI) m/z 492.5 (M + H)+.
mp 110-115℃ (融解), [α]25 D +45.1° (c 0.27, CH3OH).Anal. (C30H36Cl2F3N3O3・1.25H2O) C, H, N. 19b 遊離塩基: 1H NMR (CDCl3) δ 7.80 (d, 2H, J = 8.7 Hz), 7.51-7.36 (m, 1H), 7.27 (s, 1H), 7.17 (d, 2H, J = 7.6 Hz), 7.10-6.96 (m, 3H), 6.43-6.23 (m, 4H). 4.30-4.14 (m, 1H), 3.84-3.74 (m, 1H), 13C NMR (CDCl3) δ 167.2, 159.2, 157.1, 156.7, 151.4, 130.6, 130.4, 129.9, 129.1, 122.5, 120.6, 118.5, 116.2, 108.6, 106.5, 103.5, 58.5, 58.5, 57.8, 54.5, 51.4, 50.9, 43.6, 30.8, 18.9, 18.0, 12.8; MS (ESI) m/z 542.6 (M + H)+.
mp 103-105℃ (融解), [α]25 D +79.3° (c 0.145, CH3OH).Anal. (C29H36Cl3N3O3・1.5H2O) C, H, N. 19c 遊離塩基: 1H NMR (CDCl3) δ 7.78 (d, 2H, J = 7.8 Hz), 7.26 (t, 1H, J = 8.0 Hz), 7.15-6.84 (m, 5H), 6.50 (d, 1H, J = 7.8 Hz), 6.43-6.25 (m, 3H), 4.31-4.16 (m, 1H), 3.82-3.70 (m, 1H), 13C NMR (CDCl3) δ 167.3, 159.4, 157.3, 157.1, 151.3, 135.3, 130.7, 130.0, 129.9, 129.0, 128.9, 124.2, 119.8, 118.5, 118.4, 117.6, 108.8, 106.7, 103.8, 58.5, 57.8, 54.4, 51.2, 50.9, 43.8, 30.9, 18.9, 18.1, 12.9; MS (ESI) m/z 508.5 (M + H)+.
mp 106-109℃ (融解), [α]25 D +60.4° (c 0.23, CH3OH).Anal. (C29H36BrCl2N3O3・1.5H2O) C, H, N. 19d 遊離塩基: 1H NMR (CDCl3) δ 7.78 (d, 2H, J = 8.7 Hz), 7.31-7.13 (m, 2H), 7.09-6.91 (m, 4H), 6.44-6.23 (m, 4H), 4.29-4.14 (m, 113C NMR (CDCl3) δ 167.2, 159.4, 157.1, 151.4, 131.0, 123.0, 129.9, 127.1, 123.0, 122.6, 118.4, 118.0, 108.5, 106.4, 103.5, 58.5, 57.8, 54.5, 51.4, 50.9, 30.8, 18.9, 18.1, 12.8; MS (ESI) m/z 552.5 (M + H)+.
mp 173℃ (融解), [α]25 D 63.8° (c 0.24, CH3OH). Anal. (C30H39Cl2N3O4 ・ 1.5 H2O) C, H, N. 19e 遊離塩基: 1H NMR (CDCl3) δ 7.81-7.65 (m, 2H), 7.09-6.70 (m, 5H), 6.41-6.24 (m, 4H), 4.28-4.13 (m, 1H), 3.75-3.58 (m, 1H), 3.16-2.88 (m, 2H), 2.80-2.65 (m, 2H), 2.64-2.51 (m, 1H), 2.45-2.24 (m, 4H), 2.06-1.92 (m, 4H), 1.00-0.92 (m, 6H), 0.86-0.76 (m, 3H); 13C NMR (CDCl3) δ 167.5, 157.1, 151.3, 149.0, 139.6, 132.0, 129.9, 129.0, 128.9, 128.6, 126.2, 122.7, 119.9, 117.2, 114.9, 114.5, 108.8, 103.7, 58.5, 54.4, 51.3, 50.9, 30.9, 18.9, 18.0, 16.1, 12.9; MS (ESI) m/z 504.6 (M + H)+.
mp 117-120℃ (融解), [α]25 D +66.4° (c 0.66, CH3OH). Anal. (C31H41Cl2N3O3・2H2O) C, H, N. 19f 遊離塩基: 1H NMR (CDCl3) δ 7.75 (d, 2H, J = 8.7 Hz), 7.03 (t, 1H, J = 8.0 Hz), 6.95 (d, 2H, J = 8.7 Hz), 6.79 (s, 1H), 6.63 (s, 2H), 6.43-6.24 (m, 4H), 4.29-4.16 (m, 1H), 3.83-3.72 (m, 1H), 3.20-3.11 (m 1H), 3.09-2.97 (m, 1H), 2.95-2.72 (m, 2H), 2.61 t, 1H, J = 11 Hz), 2.51-2.30 (m, 3H), 2.28 (s, 6H), 2.11-1.98 (m, 1H), 1.03-0.93 (m, 6H), 0.88 (d, 3H, J = 6.5 Hz);13C NMR (CDCl3) δ 166.2, 159.4, 156.0, 154.8, 150.2, 138.7, 128.7, 127.9, 127.6, 124.8, 116.6, 116.2, 107.4, 105.3, 102.4, 57.3, 56.7, 53.3, 50.1, 49.7, 42.4, 29.7, 20.1, 17.7, 16.9, 11.7; MS (ESI) m/z 502.8 (M + H)+.
mp 124-130℃ (融解), [α]25 D 46.6° (c 0.50, CH3OH). Anal. (C31H41Cl2N3O3・2 H2O) C, H, N. 19g 遊離塩基: 1H NMR (CDCl3) δ 7.68 (s, 1H), 7.55 (d, 2H, J = 8.4 Hz), 7.19 (t, 1H, J = 7.7 Hz), 7.03 (t, 1H, J = 8.0 Hz), 6.91 (d, 1H, J = 7.5 Hz), 6.81 (d, 1H, J = 8.4 Hz), 6.75 (s, 1H), 6.42-6.28 (m, 5H), 4.29-4.15 (m, 1H), 3.84-3.72 (m, 1H), 3.15 (d, 1H, J = 11.4 Hz), 3.03 (t, 1H, J = 10.3 Hz), 2.84-2.72 (m 2H), 2.65-2.53 (m, 1H), 2.47-2.32 (m, 3H), 2.31 (s, 3H), 2.27 (s, 3H)2.12-1.98 (m, 1H), 1.02-0.95 (m, 6H), 0.90 (d, 3H, J = 6.4 Hz); 13C NMR (CDCl3) δ 167.6, 157.9, 157.2, 156.8, 151.4, 140.1, 130.3, 129.9, 129.7, 129.6, 129.5, 125.9, 124.2, 119.1, 118.1, 115.4, 108.5, 106.5, 103.6, 58.6, 58.6, 57.9, 54.5, 51.3, 50.9, 43.7, 43.7, 30.8, 21.4, 18.9, 18.1, 16.3, 12.8; MS (ESI) m/z 502.8 (M + H)+.
mp 128-131℃, [α]25 D 54.0° (c 0.73, CH3OH). Anal. (C31H41Cl2N3O4・2 H2O) C, H, N. 19h 遊離塩基: 1H NMR (CDCl3) δ 7.53 (d, 1H, J = 1.9 Hz), 7.27-7.14 (m, 2H), 7.03 (t, 1H, J = 8.0 Hz), 6.90 (d, 1H, J = 7.6 Hz), 6.86 (d, 1H, J = 8.3 Hz), 6.81-6.71 (m, 2H), 6.42-6.28 (m, 4H), 4.28-4.16 (m, 1H), 3.84 (s, 3H), 3.83-3.72 (m, 1H), 3.14 (d, 1H, J = 11.8 Hz), 3.01 (t, 1H, J = 10.7 Hz), 2.83-2.71 (m, 2H), 2.64-2.52 (m, 1H), 2.47-2.27 (m, 3H), 2.30 (s, 3H), 2.11-1.98 (m, 1H), 1.03-0.94 (m, 6H), 0.90 (d, 3H, J = 6.4 Hz); 13C NMR (CDCl3) δ 167.5, 157.3, 156.8, 151.4, 151.1, 148.7, 139.9, 130.8, 129.9, 129.4, 124.2, 119.1, 118.9, 118.9, 115.2, 112.3, 108.5, 106.6, 103.7, 101.6, 58.6, 57.9, 56.6, 54.5, 51.5, 50.9, 43.7, 30.8, 21.4, 19.0, 18.9, 18.1, 18.0, 14.2, 12.8; MS (ESI) m/z 518.7 (M + H)+.
mp 195-200℃, [α]25 D 58.5° (c 1.07, CH3OH). Anal. (C30H39Cl2N3O4・1.5 H2O) C, H, N. 19i 遊離塩基: 1H NMR (CDCl3) δ 7.42 (s, 1H), 7.23-7.10 (m, 2H), 7.01 (t, 1H, J = 7.8 Hz), 6.93 (d, 1H, J = 7.4 Hz), 6.77 (s, 1H), 6.71 (t, 2H, J = 8.7 Hz), 6.55 (bs, 1H), 6.45-6.32 (m, 3H), 4.33-4.19 (m, 1H), 3.52 (bs, 1H), 3.12-3.02 (m, 1H), 2.96-2.83 (m, 1H), 2.67-2.47 (m, 4H), 2.39-2.25 (m, 3H), 2.29 (s, 3H), 2.01-1.88 (m, 1H), 1.00-0.91 (m, 6H), 0.81 (d, 3H, J = 6.3 Hz); 13C NMR (CDCl3) δ 168.0, 157.3, 156.1, 151.5, 147.4, 146.9, 140.3, 131.1, 129.8, 129.7, 124.9, 119.2, 119.1, 119.1, 118.1, 115.7, 115.6, 107.7, 58.9, 53.9, 51.4, 51.2, 31.2, 21.4, 19.1, 19.1, 17.9, 13.8; MS (ESI) m/z 504.5 (M + H)+.
mp 164-167℃ (融解), [α]25 D +46.6° (c 0.35, CH3OH).Anal. (C31H41Cl2N3O3・H2O) C, H, N. 19j 遊離塩基: 1H NMR (CDCl3) δ 7.39 (d, 1H, J = 8.2 Hz), 7.22 (t, 1H, J = 8.0 Hz), 7.06 (t, 1H, J = 8.0 Hz), 6.95 (d, 1H, J = 7.4 Hz), 6.85-6.74 (m, 3H), 6.43 (dd, 1H, J = 8.3, 1.6 Hz), 6.36 (s, 1H), 6.29 (dd, 1H, J = 7.9, 1.8 Hz), 5.81 (bd, 1H, J = 6.8 Hz), 4.30-4.16 (m, 1H), 3.89-3.77 (m, 1H), 13C NMR (CDCl3) δ 169.8, 158.7, 156.9, 156.5, 151.5, 140.1, 138.7, 129.9, 129.6, 128.5, 124.6, 120.8, 120.0, 116.4, 115.4, 108.8, 106.3, 103.6, 59.4, 58.4, 54.6, 51.2, 51.0, 43.9, 30.6, 21.4, 20.2, 19.1, 17.8, 13.1; MS (ESI) m/z 502.8 (M + H)+.
mp 99-102℃ (融解), [α]25 D +82.3° (c 0.265, CH3OH).Anal. (C31H41Cl2N3O4・0.5H2O) C, H, N. 19k 遊離塩基: 1H NMR (CDCl3) δ 8.11 (d, 1H, J = 8.7 Hz), 7.83 (d, 1H, J = 8.4 Hz), 7.29-7.19 (m, 1H), 7.07-6.95 (m, 2H, 6.89-6.80 (m, 2H), 6.64-6.53 (m, 2H), 6.42-6.26 (m, 3H), 4.37-4.25 (m, 1H), 3.89 (s, 3H), 3.82-3.70 (m, 1H), 13C NMR (CDCl3) δ 165.1, 161. 6, 158.9, 157.4, 155.7, 151.5, 140.2, 133.8, 129.8, 129.7, 125.2, 120.5, 116.9, 116.5, 110.2, 108.4, 106.4, 103. 7, 101.7, 59.5, 58.7, 56.1, 54.0, 51.5, 51.1, 43.8, 43.8, 30.0, 21.4, 19.4, 17.3, 12.7; MS (ESI) m/z 518.7 (M + H)+.
mp 119-123℃ (融解), [α]25 D +81.8° (c 0.08, CH3OH).Anal. (C30H39Cl2N3O4・EtOAc) C, H, N. 19l 遊離塩基: 1H NMR (CDCl3) δ 7.70 (d, 1H, J = 8.0 Hz), 7.54 (d, 1H, J = 8.2 Hz), 7.23 (t, 1H, J = 7.7 Hz), 7.12 (d, 1H, J = 8.0 Hz), 7.06-6.95 (m, 2H), 6.88-6.78 (m, 2H), 6.46-6.25 (m, 5H), 4.37-4.17 (m, 1H), 13C NMR (CDCl3) 163.5, 163.0, 157.2, 155.1, 140.2, 130.1, 129.6, 129.0, 126.0, 125.5, 121.1, 117.4, 108.8, 105.8, 57.8, 50.8, 31.2, 31.2, 21.3, 18.9, 18.3; MS (ESI) m/z 504.6 (M + H)+.
mp 95-97℃ (融解), [α]25 D +55.2° (c 0.29, CH3OH).Anal. (C30H39Cl2N3O5・H2O) C, H, N. 19m 遊離塩基: 1H NMR (CDCl3) δ 7.50 (s, 1H), 7.20 (d, 1H, J = 8.3 Hz), 7.06-6.98 (3H, m), 6.88-6.78 (m, 3H), 6.45-6.23 (m, 4H), 5.71 (bs, 2H), 4.29-4.14 (m, 1H), 3.79 (s, 3H), 3.75-3.62 (m, 1H), 3.15-2.24 (m, 8H), 2.07-1.93 (m, 1H), 1.01-0.93 (m, 6H), 0.85 (d, 3H, J = 6.3 Hz); 13C NMR (CDCl3) δ 167.4, 157.2, 151.4, 150.5, 148.6, 147.6, 143.7, 131.0, 129.9, 125.2, 125.2, 120.5, 119.1, 119.0, 118.4, 116.8, 116.7, 112.2, 108.8, 106.7, 103.8, 60.5, 58.6, 57.9, 56.1, 54.4, 51.5, 50.9, 43.9, 32.6, 30.9, 21.0, 18.9, 18.1, 14.2, 12.9; MS (ESI) m/z 520.6 (M + H)+.
mp 153-157℃ (融解), [α]25 D +68° (c 0.053, CH3OH). Anal. (C29H36Cl3N3O4・0.5 H2O) C, H, N. 19n 遊離塩基: 1H NMR (CDCl3) δ 7.83 (s, 1H), 7.55 (d, 1H, J = 8.6 Hz), 7.12-6.99 (m, 3H), 6.88-6.78 (m, 3H), 6.44-6.21 (m, 4H), 4.26-4.11 (m, 1H), 3.74-3.62 (m, 1H), 3.16-2.91 (m, 2H), 2.78-2.65 (m, 2H), 2.64-2.50 (m, 1H), 2.49-2.26 (m, 3H), 2.09-1.94 (m, 1H), 1.00-0.93 (m, 6H), 0.82 (d, 3H, J = 6.5 Hz); 13C NMR (CDCl3) δ 166.1, 156.9, 155.2, 151.4, 147.6, 142.5, 123.0, 129.6, 126.8, 125.9, 120.8, 119.5, 117.9, 117.1, 109.0, 106.6, 58.4, 57.9, 54.4, 51.5, 50.9, 43.9, 30.9, 18.9, 18.1, 14.2, 13.0; MS (ESI) m/z 524.7 (M + H)+.
mp 100-103℃ (融解), [α]25 D +60.6° (c 0.18, CH3OH).Anal. (C31H41Cl2N3O5・H2O) C, H, N. 19o 遊離塩基: 1H NMR (CDCl3) δ 7.49 (d, 1H, J = 1.7 Hz), 7.21 (dd, 1H, J = 8.3, 1.7 Hz), 7.01 (t, 1H, J = 8.3 Hz), 6.92-6.78 (m, 3H), 6.69-6.66 (m, 1H), 6.46-6.28 (m, 4H), 4.29-4.14 (m, 1H), 3.79 (s, 3H), 3.75-3.63 (m, 1H),3.15-2.81 (m, 2H), 2.72 (d, 2H, J = 10.2 Hz), 2.57 (t, 1H, J = 11.2 Hz), 2.50-2.25 (m, 3H), 2.18 (s, 3H), 2.08-1.93 (m, 1H), 1.00-0.94 (m, 6H), 0.85 (d, 3H, J = 6.4 Hz); 13C NMR (CDCl3) δ 167.5, 157.2, 151.4, 150.5, 148.7, 145.2, 143.3, 130.9, 130.1, 129.9, 125.6, 119.7, 119.0, 118.3, 116.4, 116.4, 112.2, 108.7, 106.7, 103.8, 60.5, 58.6, 57.9, 56.1, 54.4, 51.5, 50.9, 43.9, 30.9, 21.0, 20.6, 19.0, 18.1, 14.2, 12.9; MS (ESI) m/z 534.3 (M + H)+.
mp 145-148℃ (融解), [α]25 D +76° (c 0.073, CH3OH). Anal. (C30H38Cl3N3O4・H2O) C, H, N. 19p 遊離塩基: 1H NMR (CDCl3) δ 7.89 (s, 1H), 7.62 (d, 1H, J = 8.2 Hz), 7.02 (t, 1H, J = 8.0 Hz), 6.94 (d, 1H, J = 7.9 Hz), 6.87 (d, 1H, J = 8.2 Hz), 6.81 (d, 1H, J = 8.6 Hz), 6.67 (s, 1H), 6.41-6.21 (m, 3H), 4.33-4.18 (m, 1H), 13C NMR (CDCl3) δ 166.2, 157.0, 155.4, 151.4, 145.2, 142.1, 130.7, 130.6, 129.9, 129.5, 126.8, 126.4, 124.4, 120.1, 117.8, 116.8, 108.9, 106.6, 103.7, 60.4, 58.5, 57.9, 54.4, 51.5, 50.9, 43.9, 30.9, 21.0, 20.6, 18.9, 18.1, 14.2, 13.0; MS (ESI) m/z 538.3 (M + H)+.
Claims (11)
- 下記式で表される化合物またはその薬学的に許容される塩:
R 31 、R 32 、R 33 、R 34 、R 35 、R 36 、R 37 およびR 38 は独立に、水素、C 1〜6 アルキル、C 2〜6 アルケニル、C 2〜6 アルキニル、または、1つもしくは複数の置換基:OH、Br、Cl、F、CN、CF 3 、NO 2 、N 3 、SO 2 CH 3 、SO 2 CF 3 、SO 2 NH 2 、C 1-6 アルキル、またはCH 2 (CH 2 ) n Y 2 'で置換されたCH 2 -アリールであり;
各Y 2 は独立に、水素、CF 3 、CO 2 R 9 、C 1〜8 アルキル、NR 10 R 11 、NHCOR 12 、NHCO 2 R 12 、CONR 13 R 14 、CH 2 OH、CH 2 OR 8 、COCH 2 R 9 、
各nは独立に0、1、2または3であり;
各R 8 、R 9 、R 10 、R 11 、R 12 、R 13 、およびR 14 は独立に、水素、C 1〜8 アルキル、または、1つもしくは複数の置換基:OH、Br、Cl、F、CN、CF 3 、NO 2 、N 3 、SO 2 CH 3 、SO 2 CF 3 、SO 2 NH 2 、C 1-6 アルキル、またはCH 2 (CH 2 ) n Y 2 'で置換されたCH 2 -アリールであり;
各Y 1 は独立に、水素、OH、Br、Cl、F、CN、CF 3 、NO 2 、N 3 、SO 2 CH 3 、SO 2 CF 3 、SO 2 NH 2 、OR 8 、CO 2 R 9 、C l-6 アルキル、NR 10 R 11 、NHCOR 12 、NHCO 2 R l2 、CONR 13 R l4 、またはCH 2 (CH 2 ) n Y 2 であるか、あるいは隣接する2つのY 1 基は-O-CH 2 -O-基または-O-CH 2 CH 2 -O-基を形成し;
各Y 2 'は独立に、水素、CF 3 またはC 1〜6 アルキルである)。 - W、X、Y、およびZが、独立に、水素、C1〜3アルキル、OC1-3アルキル、F、OH、Br、Cl、CN、CF3、NO2、SO2CH3、SO2CF3、またはSO2NH2である、請求項1に記載の化合物。
- 下記式で表される化合物またはその薬学的に許容される塩:
R 31 、R 32 、R 33 、R 34 、R 35 、R 36 、R 37 およびR 38 は独立に、水素、C 1〜6 アルキル、C 2〜6 アルケニル、C 2〜6 アルキニル、または、1つもしくは複数の置換基:OH、Br、Cl、F、CN、CF 3 、NO 2 、N 3 、SO 2 CH 3 、SO 2 CF 3 、SO 2 NH 2 、C 1-6 アルキル、またはCH 2 (CH 2 ) n Y 2 'で置換されたCH 2 -アリールであり;
各Y 2 は独立に、水素、CF 3 、CO 2 R 9 、C 1〜8 アルキル、NR 10 R 11 、NHCOR 12 、NHCO 2 R 12 、CONR 13 R 14 、CH 2 OH、CH 2 OR 8 、COCH 2 R 9 、
各nは独立に0、1、2または3であり;
各R 8 、R 9 、R 10 、R 11 、R 12 、R 13 、およびR 14 は独立に、水素、C 1〜8 アルキル、または、1つもしくは複数の置換基:OH、Br、Cl、F、CN、CF 3 、NO 2 、N 3 、SO 2 CH 3 、SO 2 CF 3 、SO 2 NH 2 、C 1-6 アルキル、またはCH 2 (CH 2 ) n Y 2 'で置換されたCH 2 -アリールであり;
各Y 1 は独立に、水素、OH、Br、Cl、F、CN、CF 3 、NO 2 、N 3 、SO 2 CH 3 、SO 2 CF 3 、SO 2 NH 2 、OR 8 、CO 2 R 9 、C l-6 アルキル、NR 10 R 11 、NHCOR 12 、NHCO 2 R l2 、CONR 13 R l4 、またはCH 2 (CH 2 ) n Y 2 であるか、あるいは隣接する2つのY 1 基は-O-CH 2 -O-基または-O-CH 2 CH 2 -O-基を形成し;
各Y 2 'は独立に、水素、CF 3 またはC 1〜6 アルキルである)。 - W、X、Y、およびZが、独立に、水素、C1〜3アルキル、OC1-3アルキル、F、OH、Br、Cl、CN、CF3、NO2、SO2CH3、SO2CF3、またはSO2NH2である、請求項3に記載の化合物。
- 下記式で表される化合物またはその薬学的に許容される塩:
R 31 、R 32 、R 33 、R 34 、R 35 、R 36 、R 37 およびR 38 は独立に、水素、C 1〜6 アルキル、C 2〜6 アルケニル、C 2〜6 アルキニル、または、1つもしくは複数の置換基:OH、Br、Cl、F、CN、CF 3 、NO 2 、N 3 、SO 2 CH 3 、SO 2 CF 3 、SO 2 NH 2 、C 1-6 アルキル、またはCH 2 (CH 2 ) n Y 2 'で置換されたCH 2 -アリールであり;
各Y 2 は独立に、水素、CF 3 、CO 2 R 9 、C 1〜8 アルキル、NR 10 R 11 、NHCOR 12 、NHCO 2 R 12 、CONR 13 R 14 、CH 2 OH、CH 2 OR 8 、COCH 2 R 9 、
各nは独立に0、1、2または3であり;
各R 8 、R 9 、R 10 、R 11 、R 12 、R 13 、およびR 14 は独立に、水素、C 1〜8 アルキル、または、1つもしくは複数の置換基:OH、Br、Cl、F、CN、CF 3 、NO 2 、N 3 、SO 2 CH 3 、SO 2 CF 3 、SO 2 NH 2 、C 1-6 アルキル、またはCH 2 (CH 2 ) n Y 2 'で置換されたCH 2 -アリールであり;
各Y 1 は独立に、水素、OH、Br、Cl、F、CN、CF 3 、NO 2 、N 3 、SO 2 CH 3 、SO 2 CF 3 、SO 2 NH 2 、OR 8 、CO 2 R 9 、C l-6 アルキル、NR 10 R 11 、NHCOR 12 、NHCO 2 R l2 、CONR 13 R l4 、またはCH 2 (CH 2 ) n Y 2 であるか、あるいは隣接する2つのY 1 基は-O-CH 2 -O-基または-O-CH 2 CH 2 -O-基を形成し;
各Y 2 'は独立に、水素、CF 3 またはC 1〜6 アルキルである)。 - W、X、Y、およびZが、独立に、水素、C1〜3アルキル、OC1-3アルキル、F、OH、Br、Cl、CN、CF3、NO2、SO2CH3、SO2CF3、またはSO2NH2である、請求項5に記載の化合物。
- 薬学的に許容される塩である、請求項1〜6のいずれか一項に記載の化合物。
- 請求項1〜6のいずれか一項に記載の化合物および薬学的に許容される担体を含む医薬組成物。
- 薬物依存症、薬物乱用、うつ病、不安症、統合失調症、肥満、および摂食障害を治療するための、請求項8に記載の医薬組成物。
- アルコール依存症、ニコチン依存症、コカイン依存症またはメタンフェタミン依存症を治療するための、請求項8に記載の医薬組成物。
- 糖尿病、糖尿病性合併症、糖尿病性網膜症、性的障害/生殖障害、てんかん性発作、高血圧症、脳出血、うっ血性心不全、睡眠障害、アテローム性動脈硬化症、関節リウマチ、脳卒中、脂質異常症、高トリグリセリド血症、高血糖症、高リポタンパク血症、物質乱用、薬物の過剰服用、強迫行動障害、または常習行為を治療するための、請求項8に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161568961P | 2011-12-09 | 2011-12-09 | |
US61/568,961 | 2011-12-09 | ||
PCT/US2012/068751 WO2013086496A2 (en) | 2011-12-09 | 2012-12-10 | 1-substituted 4-arylpiperazine as kappa opioid receptor antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015509077A JP2015509077A (ja) | 2015-03-26 |
JP6061948B2 true JP6061948B2 (ja) | 2017-01-18 |
Family
ID=48575072
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014546171A Expired - Fee Related JP6061948B2 (ja) | 2011-12-09 | 2012-12-10 | κオピオイド受容体アンタゴニストとしての1−置換4−アリールピペラジン |
Country Status (7)
Country | Link |
---|---|
US (1) | US9512105B2 (ja) |
EP (1) | EP2773352B1 (ja) |
JP (1) | JP6061948B2 (ja) |
AU (1) | AU2012347416B2 (ja) |
CA (1) | CA2858752C (ja) |
ES (1) | ES2631607T3 (ja) |
WO (1) | WO2013086496A2 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011106039A1 (en) * | 2010-02-24 | 2011-09-01 | Research Triangle Institute | Arylpiperazone opioid receptor antagonists |
US9594070B2 (en) * | 2013-11-05 | 2017-03-14 | Spectrum Tracer Services, Llc | Method using halogenated benzoic acid esters and aldehydes for hydraulic fracturing and for tracing petroleum production |
MX2016012477A (es) | 2014-03-31 | 2017-05-04 | Ceraloc Innovation Ab | Tablas y paneles compuestos. |
US10017684B2 (en) * | 2016-04-20 | 2018-07-10 | Spectrum Tracer Services, Llc | Method and compositions for hydraulic fracturing and for tracing formation water |
US11266627B1 (en) | 2021-05-04 | 2022-03-08 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
US20220370409A1 (en) | 2021-05-04 | 2022-11-24 | Janssen Pharmaceuticals, Inc. | Compositions And Methods For The Treatment Of Depression |
US11998524B2 (en) | 2022-03-07 | 2024-06-04 | Janssen Pharmaceuticals, Inc. | Forms of aticaprant |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2052890T3 (es) * | 1988-10-10 | 1994-07-16 | Akzo Nv | Un metodo para la sintesis de compuestos aromaticos di- y trisubstituidos. |
IT1266582B1 (it) * | 1993-07-30 | 1997-01-09 | Recordati Chem Pharm | Derivati (di)azacicloesanici e diazacicloeptanici |
WO1999045925A1 (en) * | 1998-03-10 | 1999-09-16 | Research Triangle Institute | Novel opiate compounds, methods of making and methods of use |
US6974824B2 (en) * | 2001-01-08 | 2005-12-13 | Research Triangle Institute | Kappa opioid receptor ligands |
SI2208727T1 (sl) * | 2002-09-19 | 2012-11-30 | Lilly Co Eli | Diaril etri kot antagonisti opioidnega receptorja |
US20040204453A1 (en) | 2003-04-14 | 2004-10-14 | Pfizer Inc | 4-Phenyl-piperidine compounds and their use as modulators of opioid receptors |
ES2318472T3 (es) | 2004-03-15 | 2009-05-01 | Eli Lilly And Company | Derivados de 5-(5-(aminoetil)-indol-1-ilmetil)-benzamida y compuestos relacionados como antagonistas del receptor opioide para el tratamiento de la obesidad. |
EP1937677A1 (en) | 2005-10-17 | 2008-07-02 | Arcadia Pharmaceuticals Inc. | Cb-1 modulating compounds and their use |
CA2713025C (en) | 2008-01-22 | 2012-12-04 | Eli Lilly And Company | Kappa selective opioid receptor antagonist |
WO2011106039A1 (en) * | 2010-02-24 | 2011-09-01 | Research Triangle Institute | Arylpiperazone opioid receptor antagonists |
-
2012
- 2012-12-10 AU AU2012347416A patent/AU2012347416B2/en not_active Ceased
- 2012-12-10 EP EP12856118.0A patent/EP2773352B1/en not_active Not-in-force
- 2012-12-10 CA CA2858752A patent/CA2858752C/en not_active Expired - Fee Related
- 2012-12-10 ES ES12856118.0T patent/ES2631607T3/es active Active
- 2012-12-10 JP JP2014546171A patent/JP6061948B2/ja not_active Expired - Fee Related
- 2012-12-10 WO PCT/US2012/068751 patent/WO2013086496A2/en active Application Filing
- 2012-12-10 US US14/364,003 patent/US9512105B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2773352B1 (en) | 2017-06-28 |
WO2013086496A3 (en) | 2014-12-18 |
CA2858752C (en) | 2019-12-31 |
ES2631607T3 (es) | 2017-09-01 |
CA2858752A1 (en) | 2013-06-13 |
US20150005315A1 (en) | 2015-01-01 |
EP2773352A4 (en) | 2015-12-16 |
AU2012347416B2 (en) | 2016-05-12 |
US9512105B2 (en) | 2016-12-06 |
AU2012347416A1 (en) | 2014-07-03 |
JP2015509077A (ja) | 2015-03-26 |
EP2773352A2 (en) | 2014-09-10 |
WO2013086496A2 (en) | 2013-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6061948B2 (ja) | κオピオイド受容体アンタゴニストとしての1−置換4−アリールピペラジン | |
JP6746107B2 (ja) | スルホンアミド誘導体またはその薬学的に許容される酸付加塩 | |
US20070078120A1 (en) | Novel piperidine derivative | |
EA005975B1 (ru) | Соединения пиперазинилпиразинов в качестве антагонистов серотонин 5-ht2 рецептора | |
WO2000064884A1 (en) | Piperidyl-imidazole derivatives, their preparations and therapeutic uses | |
SK1142003A3 (en) | Carboxamide compounds and their use as antagonists of a human 11CBY receptor | |
WO2003087044A2 (en) | Novel carboxamide compounds for use in mch receptor related disorders | |
US20130012716A1 (en) | Substituted acetophenones useful as pde4 inhibitors | |
WO2006016218A1 (en) | Aryl or heteroaryl carbonyl derivatives derivatives useful as vanilloid receptor 1 (vr1) antagonists | |
US9750738B2 (en) | Arylpiperazine opioid receptor antagonists | |
US10377698B2 (en) | Diphenethylamine derivatives which are inter alia useful as analgesics and method for their production | |
KR20010086465A (ko) | 3,3-비아릴피페리딘 및 2,2-비아릴모르폴린 유도체 | |
FI97617C (fi) | Menetelmä uusien terapeuttisesti käyttökelpoisten N-aryylipiperatsiiniasetamidijohdannaisten valmistamiseksi | |
AU740662B2 (en) | 1,4-disubstituted piperazines | |
CA2703893A1 (en) | Inhibitors of 17beta-hydroxysteroid dehydrogenase | |
JP2014518281A (ja) | 電位依存性ナトリウムチャネル遮断薬 | |
EP3129345B1 (en) | Metabotropic glutamate receptor positive allosteric modulators (pams) and uses thereof | |
JP2000516634A (ja) | カッパアゴニストとしてのピロリジニルおよびピロリニルエチルアミン化合物 | |
JP2007176933A (ja) | 医薬組成物 | |
WO2014076038A1 (en) | Novel acetamide derivatives as trp channel antagonists | |
CN111548313A (zh) | 预防和治疗慢性疼痛药物的胍类化合物 | |
ZA200308638B (en) | 4(Phenyl-piperazinyl-methyl)benzamide derivatives and their use for the treatment of pain anxiety or gastrointestinal disorders. | |
MXPA99003103A (en) | 1,4-disubstituted piperazines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151120 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160609 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160715 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161017 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20161114 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161213 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6061948 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |